The company clinched almost $4 million seed funding after a second close and cornered markets worth billions with an IP-centric business model echoing Cambridge technology great Arm.
Mogrify can convert any mature cell type into any other mature cell type without going through a pluripotent stem cell – or even a progenitor cell-state.
In February 2019 Mogrify unveiled Dr Darrin Disley as CEO. Dr Disley previously headed up gene editing world leader Horizon Discovery.
Mogrify’s leadership team is of significant commercial and scientific calibre. The company was founded by leading academics in bioinformatics, Professor Julian Gough (LMB, Cambridge, UK), cell reprogramming, Professor Jose Polo (Monash University, Melbourne, AU), and machine learning, Assistant Professor Owen Rackham (Duke-NUS, Singapore), and is chaired by Professor Steve Jackson – Frederick James Quick Professor of Biology (University of Cambridge), head of CRUK Laboratories (Gurdon Institute), founder of KuDOS Pharmaceuticals, co-inventor of Olaparib (Lynparza®), founder of Mission Therapeutics and co-founder of Ahren.